Valneva SE Prepares for Major Milestone

Valneva SE, a biotechnology firm listed on the NYSE Euronext Paris, announced that it will report its consolidated financial results for the full year 2025 on March 18 2026. The company’s management has emphasized the importance of this disclosure as part of a broader investor‑relations effort that coincides with the upcoming presentation of Phase‑3 data for its Lyme disease vaccine candidate, VLA15.

Upcoming Financial Disclosure

  • Reporting Date: March 18 2026
  • Context: The results will cover the full year 2025, providing investors with an updated view of revenue, profitability, and cash‑flow positions.
  • Relevance: Valneva’s financial statements will also serve as a backdrop to the company’s discussion of its clinical pipeline, particularly the VLA15 program.

Focus on the VLA15 Phase‑3 Programme

Valneva’s Phase‑3 data release is scheduled for the first half of 2026. The company is coordinating a road‑show that will begin on March 10 in Boston, with subsequent conferences in Miami and Amsterdam. The program, known as the VALOR study, has enrolled 9,437 participants aged five and older and evaluates an outer surface protein A (OspA) vaccine targeting the six most common Borrelia burgdorferi serotypes in North America and Europe.

Key points of the programme include:

  • Regulatory Pathway: If the study results are positive, Valneva and its partner Pfizer plan to submit regulatory applications to both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) within the same calendar year.
  • Commercial Outlook: A successful regulatory outcome could enable a market launch before the 2028 tick‑bites season, positioning the vaccine as the first commercial Lyme‑borreliosis product worldwide.
  • Historical Support: The FDA had granted the VLA15 program Fast‑Track designation in 2017, underscoring the therapeutic significance of the candidate.

Financial Performance and Outlook

  • 2025 Revenue: €174.7 million, with product sales contributing €157.9 million.
  • 2026 Revenue Forecast: The management anticipates a decline to a range of €155–170 million, primarily due to the expiration of third‑party sales contracts.
  • Core Vaccine Sales: Sales of Valneva’s own travel vaccines—IXIARO and DUKORAL—are projected to grow by 9 percent, though this growth is insufficient to offset the projected decline from other revenue streams.
  • Cash Position: Cash and cash equivalents fell from €168.3 million at the end of 2024 to €109.7 million at the end of 2025. A successful refinancing of debt has improved liquidity, but the company remains attentive to maintaining adequate cash reserves in light of upcoming clinical milestones.

Market Reaction

The stock has closed at €4.57 as of March 5 2026, reflecting a 19 percent increase from the start of the year. Despite this upward trend, analysts note that the company’s balance sheet signals caution: decreasing cash balances and a projected revenue decline for 2026 may temper investor enthusiasm until the VLA15 Phase‑3 results are available.

Governance Update

On February 28 2026, Valneva SE released a declaration of shares and voting rights, reinforcing transparency in its corporate governance practices and ensuring alignment with shareholder expectations.

These developments position Valneva SE at a pivotal juncture, where the outcome of a single Phase‑3 study could redefine its market trajectory. Investors and market observers will monitor the forthcoming financial results and clinical data releases closely to gauge the company’s long‑term prospects.